Research programme: autologous T cell cancer therapeutics - Amgen/Kite Pharma

Drug Profile

Research programme: autologous T cell cancer therapeutics - Amgen/Kite Pharma

Alternative Names: KITE-796

Latest Information Update: 15 Jul 2016

Price : $50

At a glance

  • Originator Amgen; Kite Pharma
  • Class CAR-T cell therapies; Gene therapies
  • Mechanism of Action Antigen receptor antagonists; Cell replacements; T-cell receptor antigen antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Haematological malignancies; Solid tumours

Most Recent Events

  • 15 Jul 2016 Preclinical trials in Haematological malignancies in USA (Parenteral) (Kite Pharma pipeline)
  • 15 Jul 2016 Preclinical trials in Solid tumours in USA (Parenteral) (Kite Pharma pipeline)
  • 02 Jun 2016 Kite Pharma licenses Cell Design Labs' Synthetic Biology Technology to develop CAR-T cell containing on/off switches for the treatment of Acute myeloid leukaemia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top